BioCentury
ARTICLE | Clinical News

ADX71149 misses in Phase IIa for anxious depression

February 8, 2014 1:14 AM UTC

Addex Therapeutics Ltd. (SIX:ADXN) said top-line data from a Phase IIa trial evaluating ADX71149 to treat major depressive disorder (MDD) with anxiety symptoms do not support further development of the compound for anxious depression. In the 121-patient trial, twice-daily oral ADX71149 for eight weeks as an adjunct to a selective serotonin reuptake inhibitor (SSRI) or a serotonin/norepinephrine reuptake inhibitor (SNRI) missed the primary endpoint of improving six-item Hamilton Anxiety Subscale (HAM-A6) scores from baseline to week four vs. placebo.

Addex said it will work with partner Janssen Research & Development LLC, a unit of Johnson & Johnson (NYSE:JNJ), to identify a development path for ADX71149, which is also in Phase IIa testing for schizophrenia. The compound is a positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2 ( mGluR2). In 2005, Addex and Janssen partnered to discover, develop and commercialize worldwide mGluR2 PAMs to treat anxiety, schizophrenia and other undisclosed indications. ...